Teva Pharmaceutical Indus Lowers FY2026 Adj EPS Guidance from $2.57-$2.77 to $1.91-$2.11 vs $2.04 Est; Raises FY2026 Sales Guidance from $16.400B-$16.800B to $16.500B-$16.850B vs $16.618B Est

Teva Pharmaceutical Indus (NYSE:TEVA) lowers FY2026 Adj EPS guidance from $2.57-$2.77 to $1.91-$2.11 vs $2.04 analyst estimate. Raises FY2026 sales outlook from $16.400 billion-$16.800 billion to $16.500 billion-$16.850 billion vs $16.618 billion estimate.